Recorded device evidence

Triopsy Actuator (TMSDGB); Triopsy Biopsy Needle (BN-1825-36-01); Triopsy Biopsy Needle (BN-1825-55-01) (K242228): indications, design and recorded evidence

The acquired K242228 file contains product-specific indications and users, recorded comparison and differences, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 41 selected decisions under primary code KNW. 41 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 106.0, median 158.0, upper quartile 215.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K242228 ↗ · this pageTriopsy Actuator (TMSDGB); Triopsy Biopsy Needle (BN-1825-36-01); Triopsy Biopsy Needle (BN-1825-55-01)2024-07-30 → 2025-01-10164Traditional
K260517 ↗Automatic Core Biopsy Instrument2026-02-17 → 2026-08-28192Traditional
K262571 ↗EnCor EnCompass™ Breast Biopsy and Tissue Removal System2026-07-24 → 2026-08-1421Special
K262792 ↗Brevera Biopsy System with CorLumina Imaging Technology (BREVDISP09)2026-08-06 → 2026-08-126Special
K260572 ↗Marrow Marxman2026-02-19 → 2026-08-04166Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K242228 · PDF page 4 ↗ Source 2

The       Triopsy     Biopsy    System          (instrument     and      needles)        is       intended         for     use       in       obtaining      biopsies   from
  the   prostate.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Recorded comparison and differences

K242228 · PDF page 6 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

Performance evidence actually described

K242228 · PDF page 6 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {'uncertain_pdf_page': 1}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK242228 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryTriopsy Actuator (TMSDGB); Triopsy Biopsy Needle (BN-1825-36-01); Triopsy Biopsy Needle (BN-1825-55-01) [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantTriopsy Medical, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeKNW [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2025-01-10 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2024-07-30 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Recorded comparison and differences — what differs in our product?

    The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

    Useful evidence: Feature-by-feature differences and the underlying cited documents; no automated predicate selection.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[44466] · record 6211cf2d2e067fc2b56ef275c7590f7da799b1b1d5d7ba4020ec147c8e739307
  • [4] Complete results array / fda-decision-context:K242228 · record whole dataset partition

FDA 510(k) summary — K242228 ↗

Thu, 06 Feb 2025 14:01:57 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot a5287ffca7021c0101d9cffb6e50d1cafc689e4ddd574ca400d01df4ecb69779

  • [2] PDF page 4 · record 0861e195b3a3b88ffc526e331193efab523f33e1dff4026c8a0ce04c9d11e846
  • [3] PDF page 6 · record ec11f95a9f61d35282cfe20545373f1e7ffbe24018f9538563a9d1de94e164f6

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Usability / Human Factors Testing